-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Boehringer Ingelheim, a global leader in animal health, announced that Junweibao® (Omeprazole Oral Paste, English trade name: GastroGard TM) has obtained the "Imported Veterinary Drug Registration Certificate" issued by the Ministry of Agriculture and Rural Affairs of China, becoming the first in the animal protection industry.
A horse-specific drug approved for introduction into the Chinese market
.
Junweibao® is a gastric ulcer drug for horses that is widely welcomed by veterinarians worldwide.
Equine gastric ulcer syndrome is a gastric ulcer caused by horses' feeding methods, diet, stress and other factors.
It is a high-risk disease for all types of horses of all ages
.
Studies have shown that the incidence rate is as high as 80% to 100% in horse racing, and as high as 11% in non-sporting horses
The main ingredient of Junweibao® is omeprazole, which can effectively inhibit gastric acid and promote the self-healing of ulcers
.
In particular, the unique patented paste formula of the product ensures the uniformity and stability of the product, and can effectively inhibit the excessive secretion of gastric acid, thereby keeping the gastric environment stable for a long time, and promoting ulcer healing.
According to the "Survey Report on the Development of China's Equestrian Industry in 2019", there are currently more than 3.
6 million horses in China, which play a role in competitions, teaching, leisure riding, tourism, products and other fields
.
More and more people, especially young people, are beginning to experience equestrian sports
Boehringer Ingelheim Animal Health is based on "rooted in China, based in China", committed to providing customers with better innovative solutions and better services, and jointly promote the progress of the industry and further improve the health of humans and animals
.
"Junweibao's approval marks the start of the company's horse business in the Chinese market, and it has also become the first multinational animal health company to enter the Chinese horse industry
Boehringer Ingelheim, as the world's number one company in the equine business, focuses on anthelmintic drugs, vaccines, therapeutic drugs and health products in the field of this species
.
In recent years, the company has successively launched a number of innovative products, such as the world's first treatment for severe asthma in horses, Aservo® EquiHaler®, and the world's first approved veterinary drug Arti that uses stem cell technology to treat equine osteoarthritis and joint degeneration.
